It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

However, a new class of medications, GLP-1 agonists, originally designed for ... studies reveal a significant overlap between the brain mechanisms driving overeating and substance dependence.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...